Pfizer在印度推出新的偏头痛药物, Pfizer launches new migraine drug in India for triptan-unresponsive adults.

辉瑞在印度推出了Rimegepant ODT，一种针对对曲普坦无反应成年人的偏头痛新疗法。 Pfizer has launched Rimegepant ODT, a new migraine treatment, in India for adults unresponsive to triptans. 75毫克的口服溶解片片可快速、持续地减轻48小时的疼痛,不会造成药物过量使用头痛。 The 75 mg orally disintegrating tablet provides rapid, sustained pain relief for up to 48 hours without causing medication overuse headaches. 它设计在没有水的情况下取水,旨在帮助病人更快地康复并恢复日常活动。 Designed to be taken without water, it aims to help patients recover faster and return to daily activities. 每年印度约有2.13亿人患上偏头痛, Migraine affects about 213 million people in India annually, causing significant productivity loss. 在一个国家,偏头痛仍然是一个重大的公共卫生和经济负担,在这个国家里,这一倡议提供了一个新的选择。 The launch offers a new option in a country where migraine remains a major public health and economic burden.